Member Info for Laura2022

Surely they can sue the former CEO for lying?

Titanic shipbuilder Harland & Wolff owed more than £160m when it collapsed into administration last month, it has been revealed.

Teneo was appointed to oversee the process at the 162-year-old holding company in September while its subsidiary firms, including its prized Belfast shipyard, will continue to trade under the control of the directors.

Now a newly-filed document with Companies House has set out how the business fell into administration and how much it owed its creditor

Yes..that makes alot of sense KingH

Amazing how PYC are helping assets achieve such incredible sales !

Great stuff KingH

So, multiple assets and important clinical trials...you wonder if one of these clients will simply buy PYC down the line ?

I don't think he holds for more than an hour tbh

That's superb KingH

Does this mean we get new payments at every milestone ?

But you bought just yesterday

;)))) unless you were lying and sold ...but didn't say

Tut tut

Ilovesushi

You've often got alot to say on placings.. any thoughts?

To raise this much in this climate is good ?

I'll be watching closely

Was happy to wait for results, looks like most of the costs were the litigation etc

This transformation has come at a cost. The Company has spent approximately AUS$2.2 million* to conclude all litigation and AUS$1.0 million* on restructuring costs during the year ended 30 June 2024 to pivot the business. This equates to a total non-recurring cash cost during the year ended 30 June 2024 of AUS$3.2 million*.

I'm assuming PYC will get further work on this lead asset

Numab Therapeutics AG

5,645 followers

1d

Numab is pleased to announce the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeutic targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell receptor associated antigen CD3. The low molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers.

Physiomics plc

1,704 followers

32m

Exciting to see the programme we worked on with Numab Therapeutics AG moving into the clinic! 🎉 Looking forward to what’s next!

Numab Therapeutics AG

5,645 followers

1d

Numab is pleased to announce the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeutic targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the T-cell receptor associated antigen CD3. The low molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers.

To learn more, please read our press release: https://lnkd.in/duQpPrCa

That was a buy at yesterday afternoons prices

Trade

I'm pretty sure the damage was done by Truss and previous Tories!!

You must the bitter loyal

56 posts on VAST since January

Says just needs the signature

Certainly getting close

I bought IES at 9p in August when it had ben hammered too far

CBG looks like a good trade soon

Today

30 October 2024 Posted in News by Press Office

Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness.

With a focus on stability, investment, and long-term growth, key announcements in the Budget included increases in NHS funding, a £520m life sciences innovative manufacturing fund, and investment in research and development, including increased funding for the National Institute for Health Research (NIHR).